Y was undertaken in Indian regional cancer centre to understand cancer-covid link in patients. Method: A total of 1565 asymptomatic patients were admitted based on thermal screening and evaluation from the screening form from June 2020 to November 2020. The RT-PCR technology was used to assess the COVID 19, and patients who tested positive for COVID 19 were transported to a hospital designated by the government for COVID 19 patients. Patients who tested negative for the COVID 19 virus were transferred to the normal cancer unit to complete their treatment. Patients who tested positive for COVID 19 were referred to the COVID hospital, where their findings were analyzed and correlated with patient age, gender, and cancer stage. Findings: Out of 1565 patients, 54 patients (3.4%) tested positive. Most of the patients are in 45–59 years age group. As female patients admitted were more in number than males, so predominance of disease is higher in female. 3 patients were symptomatic after admission and 2 were severe and were admitted to the ICU with ventilations. 8 patients died in Cancer and one patient died in COVID 19. Interpretation: As only 3.4% patients tested positive and only one patient out of 54 had died, so cancer is found not to be a comorbid condition towards COVID 19 patients in the Indian population studied. Funding: This project is not funded HIGHLIGHTS 54 patients out of 1565 have been COVID19 positive i.e. (3.4%) COVID Positive.Majority of patients (94.4%) where asymptomatic and 5.6% patients were symptomatic after the admission.ITU admission was not needed for 96.3% patients and ITU admission was done in 3.75% patients.83.3% patients were discharged alive, 14.8% patients died due to cancer and 1.9% patients died due to COVID 19.Our study cohort represented that cancer is not a comorbid condition in COVID-19 infected patients....
1 July 2024 in Journal of Current Oncological Trends
Introduction: Squamous cell carcinoma (SCC) represents the most common type of head-and-neck cancer comprising approximately 90% of all head-and-neck malignancies. More recently, oral SCC has climbed to the sixth most common global malignancy as of 2016. As per recent GLOBACAN 2018, 119992 new cases of oral cavity cancer are diagnosed every year, and around 72,000 die every year. Oral cancer is among the top three cancers in India. Aims: The aim of the study was to correlate and compare the radiological, and the pathological parameters in assessing the depth of invasion (DOI). Methodology: The present study was a prospective, nonrandomized, observational study. This study was conducted from January 2021 to March 2023 at Department of Chittaranjan National Cancer Institute, Kolkata. A total of 54 patients were included in this study. Results: We found that most of the patients had magnetic resonance imaging (MRI) (size) in T4aN2c (12 [22.2%]) and though it was statistically significant (P = 0.00424), (z = 2.8647). We examined that the majority of the patients had histopathology (HPE) (size) in pT1N0 (19 [35.2%]) but this was statistically significant (P < 0.00001), (z = 4.1332). In our study, the mean DOI MRI (mm) of patients was (15.8370 ± 7.8520), mean DOI HPE (mm) of patients was (12.9444 ± 6.5052), mean circumferential resection margin (other features on HPE) (mm) of patients was (7.2600 ± 3.6242), and mean positive nodal status (other features on HPE) of patients was (1.8519 ± 2.5134). The mean total nodal status (other features on HPE) of patients was (49.7222 ± 19.1079) and mean worst pattern of invasion (other features on HPE) of patients was (4.0000 ± 0.7268). We found that mean DOI MRI mm was significantly higher in 51–60 years of age (20.1308 ± 11.6743) compared to 31–40 years of age (17.1765 ± 5.6925), 41–50 years of age (14.9571 ± 2.8832), 71–80 years of age (13.2000 ± 6.2626), 61–70 years of age (12.0000 ± 3.4641), and ≤ 30 years of age (6.0000 ± 0.0000) (P = 0.0353). Conclusion: This study showed a strong correlation between MRI and HPE in DOI in all stages, especially when DOI was >5 mm, but for overall stage, MRI tended to significantly overestimate the disease burden.
1 July 2024 in Journal of Current Oncological Trends
Resistance to chemotherapy continues to be a significant challenge for cancer treatment and a contributing factor to treatment failures and tumor progression. Recently, the gut microbiome has emerged as an important modulator of the response to chemotherapy. Numerous pre-clinical and clinical studies have demonstrated a direct association between gut microbiota composition and therapy effectiveness in many cancer types, such as colorectal, breast, pancreatic, gastric, and lung cancers, melanoma, and hematological cancers. Gut microbiota effectively regulate the efficiency of chemotherapeutic agents in various ways, either by biotransformation of chemotherapeutic agents or modulation of host immunity. In addition, microbial metabolites such as short-chain fatty acids, secondary bile acids, and tryptophan metabolites are also involved in the regulation of chemotherapy response through modulating apoptosis, immunity, and epithelial–mesenchymal transition. Finally, dysbiosis induced by chemotherapy and antibiotics has also been reported to reduce the effectiveness of therapy. This review will emphasize the ways in which gut microbiota can modulate chemotherapeutic response and induce chemoresistance. Understanding the interactions between chemotherapeutic drugs and the gut microbiota can help to enhance the efficiency of chemotherapy and find more appropriate personalized treatments.
1 January 2025 in Journal of Current Oncological Trends